NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022

Deborah K. Armstrong(Sidney Kimmel Comprehensive Cancer Center), Ronald D. Alvarez(Breast Cancer Research Foundation), Floor Backes(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jamie N. Bakkum‐Gamez, Lisa Barroilhet(University of Wisconsin Carbone Cancer Center), Kian Behbakht(University of Colorado Cancer Center), Andrew Berchuck(Cancer Institute (WIA)), Lee-may Chen(UCSF Helen Diller Family Comprehensive Cancer Center), Viola C. Chitiyo(Memorial Sloan Kettering Cancer Center), Mihaela Cristea(City Of Hope National Medical Center), Maria C. DeRosa, Eric Eisenhauer(Massachusetts General Hospital), David M. Gershenson(The University of Texas MD Anderson Cancer Center), Heidi J. Gray(Fox Chase Cancer Center), Rachel N. Grisham(Memorial Sloan Kettering Cancer Center), Ardeshir Hakam(Moffitt Cancer Center), Angela Jain(Fox Chase Cancer Center), Amer Karam(Cancer Institute (WIA)), Gottfried E. Konecny(University of Colorado Cancer Center), Charles A. Leath(University of Colorado Cancer Center), Gary S. Leiserowitz(UC Davis Comprehensive Cancer Center), Joyce F. Liu(Dana-Farber Brigham Cancer Center), Lainie P. Martin(University of Pennsylvania), Daniela Matei(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Michael McHale(UC San Diego Health System), Karen McLean(University of Michigan), David S. Miller(Southwestern Medical Center), Sanja Percac‐Lima(Massachusetts General Hospital), Steven W. Remmenga(Susan Thompson Buffett Foundation), John O. Schorge(St. Jude Children's Research Hospital), Daphne Stewart(City Of Hope National Medical Center), Premal H. Thaker(Barnes-Jewish Hospital), Roberto Vargas(Cleveland Clinic), Andrea Wahner Hendrickson, Theresa L. Werner(University of Utah), Emese Zsíros, Mary A. Dwyer(National Comprehensive Cancer Network), Lisa E. Hang(National Comprehensive Cancer Network)
Journal of the National Comprehensive Cancer Network
September 1, 2022
10.6004/jnccn.2022.0047
Cited by 396Open Access
Full Text

Abstract

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.

Related Papers

No related papers found

Powered by citation graph analysis